Imatinib mesylate

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Myelofibrosis

Conditions

Myelofibrosis, Myeloid Metaplasia, Agnogenic Myeloid Metaplasia, Chronic Myelomonocytic Leukemia

Trial Timeline

May 1, 2002 → Dec 1, 2008

NCT ID

NCT00136409

About Imatinib mesylate

Imatinib mesylate is a phase 2 stage product being developed by Novartis for Myelofibrosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00136409. Target conditions include Myelofibrosis, Myeloid Metaplasia, Agnogenic Myeloid Metaplasia.

What happened to similar drugs?

2 of 19 similar drugs in Myelofibrosis were approved

Approved (2) Terminated (3) Active (14)

✅ruxolitinib + panobinostatNovartisApproved

✅INC424NovartisApproved

🔄Placebo for Navitoclax + Ruxolitinib + NavitoclaxAbbViePhase 3

🔄Navitoclax + Ruxolitinib + Best Available Therapy (BAT)AbbViePhase 3

❌Ruxolitinib + Ruxolitinib PlaceboNovartisPhase 3

🔄INC424NovartisPhase 3

🔄Pelabresib + Ruxolitinib + PlaceboNovartisPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01742299	Approved	Active	Mar 26, 2013	Apr 21, 2033	GIST and CML
NCT00867113	Phase 2	Completed	Jul 22, 2009	Dec 20, 2016	Gastrointestinal Stromal Tumor (GIST)
NCT00732784	Phase 1	Completed	Nov 1, 2008	Dec 1, 2012	Healthy
NCT01172548	Phase 2	Completed	Aug 1, 2008	Mar 1, 2014	Gastrointestinal Stromal Tumors
NCT01483014	Phase 2	Completed	Jun 1, 2008	Jan 1, 2012	Gastrointestinal Stromal Tumors
NCT00684411	Phase 2	Completed	Jun 1, 2008	Oct 1, 2013	T Cell Non-Hodgkin Lymphoma
NCT01545427	Phase 2	Terminated	Apr 1, 2008	Dec 1, 2008	Scleroderma
NCT00479934	Phase 2	Completed	Dec 1, 2007	Dec 1, 2010	Scleroderma, Localized
NCT00677092	Phase 2	Completed	Dec 1, 2007	Jul 1, 2009	Nephrogenic Systemic Fibrosis
NCT00555581	Phase 2	Completed	Aug 1, 2007	Dec 1, 2011	Systemic Sclerosis
NCT00510354	Approved	Completed	Oct 1, 2006	Nov 1, 2012	Progressive Gastrointestinal Stromal Tumor
NCT00427583	Phase 2/3	Terminated	May 1, 2006	—	Malignant Peripheral Nerve Sheath Tumors
NCT00124748	Phase 3	Terminated	Jun 1, 2005	Nov 1, 2010	Leukemia, Myeloid, Chronic Phase
NCT00171899	Approved	Completed	Apr 1, 2005	Jun 1, 2007	Chronic Myelogenous Leukemia
NCT00171912	Phase 2	Completed	Sep 1, 2004	Jan 1, 2012	Hypereosinophilic Syndrome
NCT00171977	Approved	Completed	Jul 1, 2004	—	Gastrointestinal Stromal Tumors
NCT00171938	Phase 2	Terminated	Apr 1, 2004	Jun 1, 2006	Glioblastoma
NCT00154349	Phase 2	Completed	Oct 1, 2003	Feb 1, 2007	Philadelphia Chromosome Positive Acute Lymphocytic Leukemia
NCT00237172	Phase 2	Completed	Sep 1, 2002	—	Gastrointestinal Stromal Tumors
NCT00171860	Phase 2	Terminated	Sep 1, 2002	—	Hypereosinophilic Syndrome

Competing Products

20 competing products in Myelofibrosis

See all competitors

Product	Company	Stage	Hype Score
Ruxolitinib + Abemaciclib	Eli Lilly	Phase 1	36
Nusivertib + Ruxolitinib + Momelotinib	Sumitomo Pharma	Phase 1/2	39
Ruxolitinib + Navitoclax	AbbVie	Phase 2	35
ABBV-744 + Navitoclax + Ruxolitinib	AbbVie	Phase 1	33
Placebo for Navitoclax + Ruxolitinib + Navitoclax	AbbVie	Phase 3	40
Mivebresib + Navitoclax + Ruxolitinib	AbbVie	Phase 1	21
Navitoclax + Venetoclax	AbbVie	Pre-clinical	26
Navitoclax + Ruxolitinib + Best Available Therapy (BAT)	AbbVie	Phase 3	44
NS-018 + Best Available Therapy	Nippon Shinyaku	Phase 2	27
AZD1480	AstraZeneca	Phase 1	29
Bomedemstat	Merck	Phase 2	31
Peginterferon alfa-2a	Merck	Phase 2	27
Bomedemstat	Merck	Phase 1/2	32
MBG453 + NIS793 + Spartalizumab + Decitabine	Novartis	Phase 1	21
PIM447 + Ruxolitinib + LEE011	Novartis	Phase 1	29
LDE225 + INC424	Novartis	Phase 1/2	32
Ruxolitinib + Siremadlin + Crizanlizumab + Sabatolimab + Rineterkib + NIS793	Novartis	Phase 1/2	24
Ruxolitinib + Ruxolitinib Placebo	Novartis	Phase 3	32
Ruxolitinib	Novartis	Pre-clinical	30
ruxolitinib	Novartis	Phase 2	35